speb/financial-data huggingface dataset:
SKIN balance_sheet (annual, 2023-12-31) — Receivables: 55029000.00
SKIN income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 242878000.00
SKIN income_statement (annual, 2023-12-31) — Reconciled Depreciation: 34675000.00
SKIN cash_flow (annual, 2023-12-31) — Repayment Of Debt: 0.00
SKIN cash_flow (annual, 2023-12-31) — Repurchase Of Capital Stock: -32395000.00
SKIN income_statement (annual, 2023-12-31) — Research And Development: 10102000.00
SKIN balance_sheet (annual, 2023-12-31) — Retained Earnings: -478867000.00
SKIN income_statement (annual, 2023-12-31) — Selling And Marketing Expense: 144496000.00
SKIN income_statement (annual, 2023-12-31) — Selling General And Administration: 275928000.00
SKIN balance_sheet (annual, 2023-12-31) — Share Issued: 122899002.00
SKIN cash_flow (annual, 2023-12-31) — Short Term Debt Issuance: 0.00
SKIN cash_flow (annual, 2023-12-31) — Short Term Debt Payments: 0.00
SKIN cash_flow (annual, 2023-12-31) — Stock Based Compensation: 22544000.00
SKIN balance_sheet (annual, 2023-12-31) — Stockholders Equity: 59390000.00
SKIN balance_sheet (annual, 2023-12-31) — Tangible Book Value: -128551000.00
SKIN income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: 248908.05
SKIN income_statement (annual, 2023-12-31) — Tax Provision: -1773000.00
SKIN income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.02
SKIN balance_sheet (annual, 2023-12-31) — Taxes Receivable: 332000.00
SKIN balance_sheet (annual, 2023-12-31) — Total Assets: 929113000.00
SKIN balance_sheet (annual, 2023-12-31) — Total Capitalization: 797762000.00
SKIN balance_sheet (annual, 2023-12-31) — Total Debt: 752289000.00
SKIN balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 59390000.00
SKIN income_statement (annual, 2023-12-31) — Total Expenses: 528908000.00
SKIN balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 869723000.00
SKIN balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 230861000.00
SKIN balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 754715000.00
SKIN income_statement (annual, 2023-12-31) — Total Operating Income As Reported: -130917000.00
SKIN balance_sheet (annual, 2023-12-31) — Total Tax Payable: 18188000.00
SKIN income_statement (annual, 2023-12-31) — Total Unusual Items: 14304000.00
SKIN income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: 14304000.00
SKIN balance_sheet (annual, 2023-12-31) — Treasury Shares Number: 0.00
SKIN balance_sheet (annual, 2023-12-31) — Working Capital: 583244000.00
SKIN cash_flow (quarterly, 2024-09-30) — Common Stock Payments: 0.00
SKIN balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 29000.00
SKIN balance_sheet (quarterly, 2024-09-30) — Derivative Product Liabilities: 558000.00
SKIN cash_flow (quarterly, 2024-09-30) — Net Common Stock Issuance: 0.00
SKIN cash_flow (quarterly, 2024-09-30) — Repurchase Of Capital Stock: 0.00
SKIN income_statement (annual, 2024-12-31) — +Operating Expense: 250070000.00
SKIN income_statement (annual, 2024-12-31) — +Total Revenue: 334294000.00
SKIN balance_sheet (annual, 2024-12-31) — Accounts Payable: 21941000.00
SKIN balance_sheet (annual, 2024-12-31) — Accounts Receivable: 27643000.00
SKIN balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -25500000.00
SKIN balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 566709000.00
SKIN balance_sheet (annual, 2024-12-31) — Allowance For Doubtful Accounts Receivable: -9597000.00
SKIN cash_flow (annual, 2024-12-31) — Amortization Cash Flow: 23740000.00
SKIN cash_flow (annual, 2024-12-31) — Amortization Of Intangibles: 23740000.00
SKIN cash_flow (annual, 2024-12-31) — Asset Impairment Charge: 28041000.00
SKIN income_statement (annual, 2024-12-31) — Average Dilution Earnings: -22671000.00
SKIN income_statement (annual, 2024-12-31) — Basic Average Shares: 123827372.00
SKIN income_statement (annual, 2024-12-31) — Basic EPS: -0.23
SKIN cash_flow (annual, 2024-12-31) — Beginning Cash Position: 523025000.00
SKIN cash_flow (annual, 2024-12-31) — Capital Expenditure: -6794000.00
SKIN balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 15960000.00
SKIN balance_sheet (annual, 2024-12-31) — Capital Stock: 12000.00
SKIN balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 370063000.00
SKIN balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 370063000.00
SKIN cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: -158341000.00
SKIN cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Investing Activities: -6794000.00
SKIN cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: 16134000.00
SKIN cash_flow (annual, 2024-12-31) — Change In Inventory: -10500000.00
SKIN cash_flow (annual, 2024-12-31) — Change In Other Working Capital: -9400000.00
SKIN cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: -43776000.00
SKIN cash_flow (annual, 2024-12-31) — Change In Prepaid Assets: 15479000.00
SKIN cash_flow (annual, 2024-12-31) — Change In Receivables: 20804000.00
SKIN cash_flow (annual, 2024-12-31) — Change In Working Capital: -27393000.00
SKIN cash_flow (annual, 2024-12-31) — Changes In Account Receivables: 20804000.00
SKIN cash_flow (annual, 2024-12-31) — Changes In Cash: -149001000.00
SKIN balance_sheet (annual, 2024-12-31) — Common Stock: 12000.00
SKIN balance_sheet (annual, 2024-12-31) — Common Stock Equity: 51803000.00
SKIN cash_flow (annual, 2024-12-31) — Common Stock Payments: 0.00
SKIN cash_flow (quarterly, 2024-12-31) — Common Stock Payments: 0.00
SKIN balance_sheet (annual, 2024-12-31) — Construction In Progress: 0.00
SKIN balance_sheet (quarterly, 2024-12-31) — Construction In Progress: 0.00
SKIN income_statement (annual, 2024-12-31) — Cost Of Revenue: 151998000.00
SKIN balance_sheet (annual, 2024-12-31) — Current Accrued Expenses: 17167000.00
SKIN balance_sheet (annual, 2024-12-31) — Current Assets: 477124000.00
SKIN balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 5147000.00
SKIN balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 5147000.00
SKIN balance_sheet (annual, 2024-12-31) — Current Deferred Liabilities: 2375000.00
SKIN balance_sheet (annual, 2024-12-31) — Current Deferred Revenue: 2375000.00
SKIN balance_sheet (annual, 2024-12-31) — Current Liabilities: 68152000.00
SKIN cash_flow (annual, 2024-12-31) — Deferred Income Tax: -3748000.00
SKIN cash_flow (annual, 2024-12-31) — Deferred Tax: -3748000.00
SKIN cash_flow (annual, 2024-12-31) — Depreciation: 9940000.00
SKIN cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 33680000.00
SKIN cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 33680000.00
SKIN balance_sheet (annual, 2024-12-31) — Derivative Product Liabilities: 488000.00
SKIN balance_sheet (quarterly, 2024-12-31) — Derivative Product Liabilities: 488000.00
SKIN income_statement (annual, 2024-12-31) — Diluted Average Shares: 123827372.00
SKIN income_statement (annual, 2024-12-31) — Diluted EPS: -0.23
SKIN income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: -51769000.00
SKIN income_statement (annual, 2024-12-31) — EBIT: -19138000.00
SKIN income_statement (annual, 2024-12-31) — EBITDA: 14542000.00
SKIN cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: -3961000.00
SKIN cash_flow (annual, 2024-12-31) — End Cash Position: 370063000.00
SKIN cash_flow (annual, 2024-12-31) — Financing Cash Flow: -158341000.00
SKIN balance_sheet (annual, 2024-12-31) — Finished Goods: 43094000.00
SKIN cash_flow (annual, 2024-12-31) — Free Cash Flow: 9340000.00
SKIN cash_flow (annual, 2024-12-31) — Gain Loss On Investment Securities: -3067000.00
SKIN cash_flow (quarterly, 2024-12-31) — Gain Loss On Investment Securities: -70000.00
SKIN income_statement (annual, 2024-12-31) — Gain On Sale Of Security: -1571000.00
SKIN balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: -6953000.00
SKIN income_statement (annual, 2024-12-31) — General And Administrative Expense: 125463000.00
SKIN balance_sheet (annual, 2024-12-31) — Goodwill: 123499000.00
SKIN balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 171011000.00
SKIN balance_sheet (annual, 2024-12-31) — Gross Accounts Receivable: 37240000.00
SKIN balance_sheet (annual, 2024-12-31) — Gross PPE: 45068000.00
SKIN income_statement (annual, 2024-12-31) — Gross Profit: 182296000.00
SKIN cash_flow (annual, 2024-12-31) — Income Tax Paid Supplemental Data: 2801000.00
SKIN balance_sheet (annual, 2024-12-31) — Income Tax Payable: 3426000.00
SKIN income_statement (annual, 2024-12-31) — Interest Expense: 10412000.00
SKIN income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 10412000.00
SKIN income_statement (annual, 2024-12-31) — Interest Income: 16644000.00
SKIN income_statement (annual, 2024-12-31) — Interest Income Non Operating: 16644000.00
SKIN cash_flow (annual, 2024-12-31) — Interest Paid Supplemental Data: 8014000.00
SKIN balance_sheet (annual, 2024-12-31) — Interest Payable: 1743000.00
SKIN balance_sheet (annual, 2024-12-31) — Inventory: 69113000.00
SKIN balance_sheet (annual, 2024-12-31) — Invested Capital: 604001000.00
SKIN cash_flow (annual, 2024-12-31) — Investing Cash Flow: -6794000.00
SKIN cash_flow (annual, 2024-12-31) — Issuance Of Debt: 0.00
SKIN balance_sheet (annual, 2024-12-31) — Leases: 12019000.00
SKIN balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 10813000.00
SKIN balance_sheet (annual, 2024-12-31) — Long Term Debt: 552198000.00
SKIN balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 563011000.00
SKIN cash_flow (annual, 2024-12-31) — Long Term Debt Issuance: 0.00
SKIN cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -156082000.00
SKIN balance_sheet (annual, 2024-12-31) — Machinery Furniture Equipment: 18727000.00
SKIN cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: 0.00
SKIN cash_flow (quarterly, 2024-12-31) — Net Common Stock Issuance: 0.00
SKIN balance_sheet (annual, 2024-12-31) — Net Debt: 182135000.00
SKIN income_statement (annual, 2024-12-31) — Net Income: -29098000.00
SKIN income_statement (annual, 2024-12-31) — Net Income Common Stockholders: -29098000.00
SKIN income_statement (annual, 2024-12-31) — Net Income Continuous Operations: -29098000.00
SKIN income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -29098000.00
SKIN income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -29098000.00
SKIN cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: -29098000.00
SKIN income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: -29098000.00
SKIN cash_flow (annual, 2024-12-31) — Net Intangibles Purchase And Sale: -6038000.00
SKIN income_statement (annual, 2024-12-31) — Net Interest Income: 6232000.00
SKIN cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: -156082000.00
SKIN cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: -156082000.00
SKIN income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: 6232000.00
SKIN cash_flow (annual, 2024-12-31) — Net Other Financing Charges: -2259000.00
SKIN balance_sheet (annual, 2024-12-31) — Net PPE: 19568000.00
SKIN cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -756000.00
SKIN balance_sheet (annual, 2024-12-31) — Net Tangible Assets: -119208000.00
SKIN balance_sheet (annual, 2024-12-31) — Non Current Deferred Assets: 3894000.00
SKIN balance_sheet (annual, 2024-12-31) — Non Current Deferred Liabilities: 396000.00
SKIN balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Assets: 3894000.00
SKIN balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Liabilities: 396000.00
SKIN income_statement (annual, 2024-12-31) — Normalized EBITDA: 16113000.00
SKIN income_statement (annual, 2024-12-31) — Normalized Income: -27550565.00
SKIN cash_flow (annual, 2024-12-31) — Operating Cash Flow: 16134000.00
SKIN cash_flow (annual, 2024-12-31) — Operating Gains Losses: -3067000.00
SKIN cash_flow (quarterly, 2024-12-31) — Operating Gains Losses: -70000.00
SKIN income_statement (annual, 2024-12-31) — Operating Income: -67774000.00
SKIN income_statement (annual, 2024-12-31) — Operating Revenue: 334294000.00
SKIN balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 124924185.00
SKIN balance_sheet (annual, 2024-12-31) — Other Current Assets: 9487000.00
SKIN balance_sheet (annual, 2024-12-31) — Other Equity Adjustments: -6953000.00
SKIN income_statement (annual, 2024-12-31) — Other Gand A: 125463000.00
SKIN income_statement (annual, 2024-12-31) — Other Income Expense: 31992000.00
SKIN balance_sheet (annual, 2024-12-31) — Other Intangible Assets: 47512000.00
SKIN cash_flow (annual, 2024-12-31) — Other Non Cash Items: -14111000.00
SKIN balance_sheet (annual, 2024-12-31) — Other Non Current Assets: 14086000.00
SKIN balance_sheet (annual, 2024-12-31) — Other Non Current Liabilities: 2321000.00
SKIN income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: 33563000.00
SKIN balance_sheet (annual, 2024-12-31) — Other Properties: 14322000.00
SKIN balance_sheet (annual, 2024-12-31) — Payables: 41319000.00
SKIN balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 58486000.00
SKIN balance_sheet (annual, 2024-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 2144000.00
SKIN income_statement (annual, 2024-12-31) — Pretax Income: -29550000.00
SKIN balance_sheet (annual, 2024-12-31) — Properties: 0.00
SKIN cash_flow (annual, 2024-12-31) — Provisionand Write Offof Assets: 5134000.00
SKIN cash_flow (annual, 2024-12-31) — Purchase Of Intangibles: -6038000.00
SKIN cash_flow (annual, 2024-12-31) — Purchase Of PPE: -756000.00
SKIN balance_sheet (annual, 2024-12-31) — Raw Materials: 26019000.00
SKIN balance_sheet (annual, 2024-12-31) — Receivables: 28461000.00
SKIN income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 151998000.00
SKIN income_statement (annual, 2024-12-31) — Reconciled Depreciation: 33680000.00
SKIN cash_flow (annual, 2024-12-31) — Repayment Of Debt: -156082000.00
SKIN cash_flow (annual, 2024-12-31) — Repurchase Of Capital Stock: 0.00
SKIN cash_flow (quarterly, 2024-12-31) — Repurchase Of Capital Stock: 0.00
SKIN income_statement (annual, 2024-12-31) — Research And Development: 6296000.00
SKIN balance_sheet (annual, 2024-12-31) — Retained Earnings: -507965000.00
SKIN income_statement (annual, 2024-12-31) — Selling And Marketing Expense: 118311000.00
SKIN income_statement (annual, 2024-12-31) — Selling General And Administration: 243774000.00
SKIN balance_sheet (annual, 2024-12-31) — Share Issued: 124924185.00
SKIN cash_flow (annual, 2024-12-31) — Stock Based Compensation: 26696000.00
SKIN balance_sheet (annual, 2024-12-31) — Stockholders Equity: 51803000.00
SKIN balance_sheet (annual, 2024-12-31) — Tangible Book Value: -119208000.00
SKIN income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: -23565.00
SKIN income_statement (annual, 2024-12-31) — Tax Provision: -452000.00
SKIN income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.02
SKIN balance_sheet (annual, 2024-12-31) — Taxes Receivable: 818000.00
SKIN balance_sheet (annual, 2024-12-31) — Total Assets: 685683000.00
SKIN balance_sheet (annual, 2024-12-31) — Total Capitalization: 604001000.00
SKIN balance_sheet (annual, 2024-12-31) — Total Debt: 568158000.00
SKIN balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 51803000.00
SKIN income_statement (annual, 2024-12-31) — Total Expenses: 402068000.00
SKIN balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 633880000.00
SKIN balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 208559000.00
SKIN balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 565728000.00
SKIN income_statement (annual, 2024-12-31) — Total Operating Income As Reported: -67774000.00
SKIN balance_sheet (annual, 2024-12-31) — Total Tax Payable: 19378000.00
SKIN income_statement (annual, 2024-12-31) — Total Unusual Items: -1571000.00
SKIN income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: -1571000.00
SKIN balance_sheet (annual, 2024-12-31) — Working Capital: 408972000.00
SKIN income_statement (quarterly, 2025-03-31) — +Operating Expense: 60603000.00
SKIN income_statement (quarterly, 2025-03-31) — +Total Revenue: 69580000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 23143000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 23258000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -26916000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 569935000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -9476000.00
SKIN cash_flow (quarterly, 2025-03-31) — Amortization Cash Flow: 4308000.00
SKIN cash_flow (quarterly, 2025-03-31) — Amortization Of Intangibles: 4308000.00
SKIN cash_flow (quarterly, 2025-03-31) — Asset Impairment Charge: 277000.00
SKIN income_statement (quarterly, 2025-03-31) — Average Dilution Earnings: 0.00
SKIN income_statement (quarterly, 2025-03-31) — Basic Average Shares: 125079470.00
SKIN income_statement (quarterly, 2025-03-31) — Basic EPS: -0.08
SKIN cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 370063000.00
SKIN cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -1145000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 14703000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Capital Stock: 12000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 373031000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 373031000.00
SKIN cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: -250000.00
SKIN cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: -1145000.00
SKIN cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: 2996000.00
SKIN cash_flow (quarterly, 2025-03-31) — Change In Account Payable: -5730000.00
SKIN cash_flow (quarterly, 2025-03-31) — Change In Inventory: 3761000.00
SKIN cash_flow (quarterly, 2025-03-31) — Change In Other Working Capital: -1999000.00
SKIN cash_flow (quarterly, 2025-03-31) — Change In Payable: -5730000.00
SKIN cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: -5730000.00
SKIN cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: 2906000.00
SKIN cash_flow (quarterly, 2025-03-31) — Change In Receivables: 3989000.00
SKIN cash_flow (quarterly, 2025-03-31) — Change In Working Capital: 2927000.00
SKIN cash_flow (quarterly, 2025-03-31) — Changes In Account Receivables: 3989000.00
SKIN cash_flow (quarterly, 2025-03-31) — Changes In Cash: 1601000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Common Stock: 12000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 46061000.00
SKIN income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 21000000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Current Accrued Expenses: 17096000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Current Assets: 469373000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 5075000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 5075000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Current Deferred Liabilities: 590000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Current Deferred Revenue: 590000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 62804000.00
SKIN cash_flow (quarterly, 2025-03-31) — Deferred Income Tax: -265000.00
SKIN cash_flow (quarterly, 2025-03-31) — Deferred Tax: -265000.00
SKIN cash_flow (quarterly, 2025-03-31) — Depreciation: 1856000.00
SKIN cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 6164000.00
SKIN cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 6164000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Derivative Product Liabilities: 139000.00
SKIN income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 125079470.00
SKIN income_statement (quarterly, 2025-03-31) — Diluted EPS: -0.08
SKIN income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -10096000.00
SKIN income_statement (quarterly, 2025-03-31) — EBIT: -6706000.00
SKIN income_statement (quarterly, 2025-03-31) — EBITDA: -542000.00
SKIN cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: 1367000.00
SKIN cash_flow (quarterly, 2025-03-31) — End Cash Position: 373031000.00
SKIN cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: -250000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Finished Goods: 41407000.00
SKIN cash_flow (quarterly, 2025-03-31) — Free Cash Flow: 1851000.00
SKIN cash_flow (quarterly, 2025-03-31) — Gain Loss On Investment Securities: -349000.00
SKIN income_statement (quarterly, 2025-03-31) — Gain On Sale Of Security: 2229000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: -5825000.00
SKIN income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 33565000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Goodwill: 124260000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 169909000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 32734000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Gross PPE: 43615000.00
SKIN income_statement (quarterly, 2025-03-31) — Gross Profit: 48580000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Income Tax Payable: 3314000.00
SKIN income_statement (quarterly, 2025-03-31) — Interest Expense: 2498000.00
SKIN income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 2498000.00
SKIN income_statement (quarterly, 2025-03-31) — Interest Income: 3028000.00
SKIN income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 3028000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Interest Payable: 3486000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Inventory: 65632000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Invested Capital: 599045000.00
SKIN cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: -1145000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Leases: 12096000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 9628000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 552984000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 562612000.00
SKIN cash_flow (quarterly, 2025-03-31) — Long Term Debt Payments: 0.00
SKIN balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 18308000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Net Debt: 179953000.00
SKIN income_statement (quarterly, 2025-03-31) — Net Income: -10096000.00
SKIN income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -10096000.00
SKIN income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -10096000.00
SKIN income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -10096000.00
SKIN income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -10096000.00
SKIN cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: -10096000.00
SKIN income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -10096000.00
SKIN cash_flow (quarterly, 2025-03-31) — Net Intangibles Purchase And Sale: -1100000.00
SKIN income_statement (quarterly, 2025-03-31) — Net Interest Income: 530000.00
SKIN cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: 0.00
SKIN cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: 0.00
SKIN income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: 530000.00
SKIN cash_flow (quarterly, 2025-03-31) — Net Other Financing Charges: -250000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Net PPE: 16699000.00
SKIN cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -45000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: -123848000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Assets: 4251000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Liabilities: 402000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 4251000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 402000.00
SKIN income_statement (quarterly, 2025-03-31) — Normalized EBITDA: -2771000.00
SKIN income_statement (quarterly, 2025-03-31) — Normalized Income: -11856910.00
SKIN cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: 2996000.00
SKIN cash_flow (quarterly, 2025-03-31) — Operating Gains Losses: -349000.00
SKIN income_statement (quarterly, 2025-03-31) — Operating Income: -12023000.00
SKIN income_statement (quarterly, 2025-03-31) — Operating Revenue: 69580000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 125246286.00
SKIN balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 7178000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Other Equity Adjustments: -5825000.00
SKIN income_statement (quarterly, 2025-03-31) — Other Gand A: 33565000.00
SKIN income_statement (quarterly, 2025-03-31) — Other Income Expense: 2289000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 45649000.00
SKIN cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 123000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 13588000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 1802000.00
SKIN income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 60000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Other Properties: 13211000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Payables: 37584000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 54680000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 2459000.00
SKIN income_statement (quarterly, 2025-03-31) — Pretax Income: -9204000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
SKIN cash_flow (quarterly, 2025-03-31) — Provisionand Write Offof Assets: 739000.00
SKIN cash_flow (quarterly, 2025-03-31) — Purchase Of Intangibles: -1100000.00
SKIN cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -45000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Raw Materials: 24225000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Receivables: 23532000.00
SKIN income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 21000000.00
SKIN income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 6164000.00
SKIN cash_flow (quarterly, 2025-03-31) — Repayment Of Debt: 0.00
SKIN income_statement (quarterly, 2025-03-31) — Research And Development: 998000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -518061000.00
SKIN income_statement (quarterly, 2025-03-31) — Selling And Marketing Expense: 26040000.00
SKIN income_statement (quarterly, 2025-03-31) — Selling General And Administration: 59605000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Share Issued: 125246286.00
SKIN cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 3476000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 46061000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: -123848000.00
SKIN income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 468090.00
SKIN income_statement (quarterly, 2025-03-31) — Tax Provision: 892000.00
SKIN income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.21
SKIN balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 274000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Total Assets: 673820000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 599045000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Total Debt: 567687000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 46061000.00
SKIN income_statement (quarterly, 2025-03-31) — Total Expenses: 81603000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 627759000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 204447000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 564955000.00
SKIN income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: -12023000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 14441000.00
SKIN income_statement (quarterly, 2025-03-31) — Total Unusual Items: 2229000.00
SKIN income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 2229000.00
SKIN balance_sheet (quarterly, 2025-03-31) — Working Capital: 406569000.00
SKIN income_statement (quarterly, 2025-06-30) — +Operating Expense: 51812000.00
SKIN income_statement (quarterly, 2025-06-30) — +Total Revenue: 78187000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 22976000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 25046000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Accumulated Depreciation: -26614000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 574535000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Allowance For Doubtful Accounts Receivable: -8014000.00
SKIN cash_flow (quarterly, 2025-06-30) — Amortization Cash Flow: 4690000.00
SKIN cash_flow (quarterly, 2025-06-30) — Amortization Of Intangibles: 4690000.00
SKIN cash_flow (quarterly, 2025-06-30) — Asset Impairment Charge: 2201000.00
SKIN income_statement (quarterly, 2025-06-30) — Average Dilution Earnings: -15546000.00
SKIN income_statement (quarterly, 2025-06-30) — Basic Average Shares: 126072603.00
SKIN income_statement (quarterly, 2025-06-30) — Basic EPS: 0.16
SKIN cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 373031000.00
SKIN cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -1552000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 13635000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Capital Stock: 12000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 212000000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 212000000.00
SKIN cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: -173361000.00
SKIN cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: -1552000.00
SKIN cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: 9646000.00
SKIN cash_flow (quarterly, 2025-06-30) — Change In Inventory: 5328000.00
SKIN cash_flow (quarterly, 2025-06-30) — Change In Other Working Capital: -1828000.00
SKIN cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: -3991000.00
SKIN cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: -2338000.00
SKIN cash_flow (quarterly, 2025-06-30) — Change In Receivables: -1708000.00
SKIN cash_flow (quarterly, 2025-06-30) — Change In Working Capital: -4537000.00
SKIN cash_flow (quarterly, 2025-06-30) — Changes In Account Receivables: -1708000.00
SKIN cash_flow (quarterly, 2025-06-30) — Changes In Cash: -165267000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Common Stock: 12000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 74002000.00
SKIN income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 29075000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Current Accrued Expenses: 13498000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Current Assets: 306107000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 5165000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 5165000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Current Deferred Liabilities: 172000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Current Deferred Revenue: 172000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 59441000.00
SKIN cash_flow (quarterly, 2025-06-30) — Deferred Income Tax: 1083000.00
SKIN cash_flow (quarterly, 2025-06-30) — Deferred Tax: 1083000.00
SKIN cash_flow (quarterly, 2025-06-30) — Depreciation: 711000.00
SKIN cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 5401000.00
SKIN cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 5401000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Derivative Product Liabilities: 349000.00
SKIN income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 140294291.00
SKIN income_statement (quarterly, 2025-06-30) — Diluted EPS: 0.03
SKIN income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 4166000.00
SKIN income_statement (quarterly, 2025-06-30) — EBIT: 22863000.00
SKIN income_statement (quarterly, 2025-06-30) — EBITDA: 28264000.00
SKIN cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: 4236000.00
SKIN cash_flow (quarterly, 2025-06-30) — End Cash Position: 212000000.00
SKIN cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: -173361000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Finished Goods: 36229000.00
SKIN cash_flow (quarterly, 2025-06-30) — Free Cash Flow: 8094000.00
SKIN cash_flow (quarterly, 2025-06-30) — Gain Loss On Investment Securities: 210000.00
SKIN income_statement (quarterly, 2025-06-30) — Gain On Sale Of Security: 4259000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: -2196000.00
SKIN income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 27452000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Goodwill: 126273000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 169762000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Gross Accounts Receivable: 33060000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Gross PPE: 41853000.00
SKIN income_statement (quarterly, 2025-06-30) — Gross Profit: 49112000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Income Tax Payable: 2676000.00
SKIN income_statement (quarterly, 2025-06-30) — Interest Expense: 4144000.00
SKIN income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 4144000.00
SKIN income_statement (quarterly, 2025-06-30) — Interest Income: 3158000.00
SKIN income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 3158000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Interest Payable: 2321000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Inventory: 59187000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Invested Capital: 437098000.00
SKIN cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: -1552000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Leases: 12249000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 8470000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Long Term Debt: 363096000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 371566000.00
SKIN cash_flow (quarterly, 2025-06-30) — Long Term Debt Payments: -410955000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Machinery Furniture Equipment: 17337000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Net Debt: 151096000.00
SKIN income_statement (quarterly, 2025-06-30) — Net Income: 19712000.00
SKIN income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 19712000.00
SKIN income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 19712000.00
SKIN income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 19712000.00
SKIN income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 19712000.00
SKIN cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: 19712000.00
SKIN income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 19712000.00
SKIN cash_flow (quarterly, 2025-06-30) — Net Intangibles Purchase And Sale: -1460000.00
SKIN income_statement (quarterly, 2025-06-30) — Net Interest Income: -986000.00
SKIN cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: -172653000.00
SKIN cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: -172653000.00
SKIN income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -986000.00
SKIN cash_flow (quarterly, 2025-06-30) — Net Other Financing Charges: -708000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Net PPE: 15239000.00
SKIN cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: -92000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: -95760000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Assets: 3157000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Liabilities: 217000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Assets: 3157000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Liabilities: 217000.00
SKIN income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 24005000.00
SKIN income_statement (quarterly, 2025-06-30) — Normalized Income: 16347390.00
SKIN cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: 9646000.00
SKIN cash_flow (quarterly, 2025-06-30) — Operating Gains Losses: 210000.00
SKIN income_statement (quarterly, 2025-06-30) — Operating Income: -2700000.00
SKIN income_statement (quarterly, 2025-06-30) — Operating Revenue: 78187000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 126764562.00
SKIN balance_sheet (quarterly, 2025-06-30) — Other Current Assets: 7794000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: -2196000.00
SKIN income_statement (quarterly, 2025-06-30) — Other Gand A: 27452000.00
SKIN income_statement (quarterly, 2025-06-30) — Other Income Expense: 22405000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Other Intangible Assets: 43489000.00
SKIN cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: -20570000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Other Non Current Assets: 13300000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Other Non Current Liabilities: 1990000.00
SKIN income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 18146000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Other Properties: 12267000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Payables: 38516000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 52014000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Pensionand Other Post Retirement Benefit Plans Current: 2090000.00
SKIN income_statement (quarterly, 2025-06-30) — Pretax Income: 18719000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Properties: 0.00
SKIN cash_flow (quarterly, 2025-06-30) — Provisionand Write Offof Assets: 838000.00
SKIN cash_flow (quarterly, 2025-06-30) — Purchase Of Intangibles: -1460000.00
SKIN cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: -92000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Raw Materials: 22958000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Receivables: 27126000.00
SKIN income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 29075000.00
SKIN income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 5401000.00
SKIN cash_flow (quarterly, 2025-06-30) — Repayment Of Debt: -410955000.00
SKIN income_statement (quarterly, 2025-06-30) — Research And Development: 1251000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -498349000.00
SKIN income_statement (quarterly, 2025-06-30) — Selling And Marketing Expense: 23109000.00
SKIN income_statement (quarterly, 2025-06-30) — Selling General And Administration: 50561000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Share Issued: 126764562.00
SKIN cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 5308000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 74002000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: -95760000.00
SKIN income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 894390.00
SKIN income_statement (quarterly, 2025-06-30) — Tax Provision: -993000.00
SKIN income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.21
SKIN balance_sheet (quarterly, 2025-06-30) — Taxes Receivable: 2080000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Total Assets: 507565000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 437098000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Total Debt: 376731000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 74002000.00
SKIN income_statement (quarterly, 2025-06-30) — Total Expenses: 80887000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 433563000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 201458000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 374122000.00
SKIN income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: -2700000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Total Tax Payable: 15540000.00
SKIN income_statement (quarterly, 2025-06-30) — Total Unusual Items: 4259000.00
SKIN income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 4259000.00
SKIN balance_sheet (quarterly, 2025-06-30) — Working Capital: 246666000.00
SKIN income_statement (quarterly, 2025-09-30) — +Operating Expense: 51876000.00
SKIN income_statement (quarterly, 2025-09-30) — +Total Revenue: 70655000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 17294000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 22206000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Accumulated Depreciation: -25063000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 576802000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Allowance For Doubtful Accounts Receivable: -7429000.00
SKIN cash_flow (quarterly, 2025-09-30) — Amortization Cash Flow: 7796000.00
SKIN cash_flow (quarterly, 2025-09-30) — Amortization Of Intangibles: 7796000.00
SKIN cash_flow (quarterly, 2025-09-30) — Asset Impairment Charge: 1165000.00
SKIN income_statement (quarterly, 2025-09-30) — Average Dilution Earnings: 0.00
SKIN income_statement (quarterly, 2025-09-30) — Basic Average Shares: 126890888.00
SKIN income_statement (quarterly, 2025-09-30) — Basic EPS: -0.09
SKIN cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 212000000.00
SKIN cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -1084000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 15592000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Capital Stock: 13000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 219397000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 219397000.00
SKIN cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: -803000.00
SKIN cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -1084000.00
SKIN cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: 9647000.00
SKIN cash_flow (quarterly, 2025-09-30) — Change In Inventory: 2025000.00
SKIN cash_flow (quarterly, 2025-09-30) — Change In Other Working Capital: -2335000.00
SKIN cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 2604000.00
SKIN cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: -678000.00
SKIN cash_flow (quarterly, 2025-09-30) — Change In Receivables: 2488000.00
SKIN cash_flow (quarterly, 2025-09-30) — Change In Working Capital: 4104000.00
SKIN cash_flow (quarterly, 2025-09-30) — Changes In Account Receivables: 2488000.00
SKIN cash_flow (quarterly, 2025-09-30) — Changes In Cash: 7760000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Common Stock: 13000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 65660000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 26000.00
SKIN income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 25021000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 20053000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Current Assets: 308367000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 5041000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 5041000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Current Deferred Liabilities: 534000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Current Deferred Revenue: 534000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 61904000.00
SKIN cash_flow (quarterly, 2025-09-30) — Deferred Income Tax: 2075000.00
SKIN cash_flow (quarterly, 2025-09-30) — Deferred Tax: 2075000.00
SKIN cash_flow (quarterly, 2025-09-30) — Depreciation: 637000.00
SKIN cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 8433000.00
SKIN cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 8433000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Derivative Product Liabilities: 139000.00
SKIN income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 126890888.00
SKIN income_statement (quarterly, 2025-09-30) — Diluted EPS: -0.09
SKIN income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -11031000.00
SKIN income_statement (quarterly, 2025-09-30) — EBIT: -4334000.00
SKIN income_statement (quarterly, 2025-09-30) — EBITDA: 4099000.00
SKIN cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: -363000.00
SKIN cash_flow (quarterly, 2025-09-30) — End Cash Position: 219397000.00
SKIN cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -803000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Finished Goods: 33145000.00
SKIN cash_flow (quarterly, 2025-09-30) — Free Cash Flow: 8563000.00
SKIN cash_flow (quarterly, 2025-09-30) — Gain Loss On Investment Securities: -210000.00
SKIN income_statement (quarterly, 2025-09-30) — Gain On Sale Of Security: 51000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: -1775000.00
SKIN income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 29250000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Goodwill: 126497000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 164478000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Gross Accounts Receivable: 29635000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Gross PPE: 41728000.00
SKIN income_statement (quarterly, 2025-09-30) — Gross Profit: 45634000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Income Tax Payable: 1495000.00
SKIN income_statement (quarterly, 2025-09-30) — Interest Expense: 6311000.00
SKIN income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 6311000.00
SKIN income_statement (quarterly, 2025-09-30) — Interest Income: 1256000.00
SKIN income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 1256000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Interest Payable: 7624000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Inventory: 56146000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Invested Capital: 429048000.00
SKIN cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -1084000.00
SKIN cash_flow (quarterly, 2025-09-30) — Issuance Of Debt: -616000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Leases: 10965000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 10551000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 363388000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 373939000.00
SKIN cash_flow (quarterly, 2025-09-30) — Long Term Debt Issuance: -616000.00
SKIN cash_flow (quarterly, 2025-09-30) — Long Term Debt Payments: 0.00
SKIN balance_sheet (quarterly, 2025-09-30) — Machinery Furniture Equipment: 16393000.00
SKIN balance_sheet (quarterly, 2025-09-30) — Net Debt: 143991000.00